melanoma

[Molecular Pharmacology] Investigators utilized a computational approach to identify inhibitors that reversed experimentally derived B-raf proto-oncogene inhibitors (BRAFi) resistance gene expression signature and demonstrated experimentally that ibrutinib re-sensitized a subset of BRAFi-resistant melanoma cells to vemurafenib.

[Cancer Research] Researchers demonstrated that the transcription factor SOX10 hindered immunogenicity of melanoma cells through the IRF4-IRF1 axis. Genetic and pharmacological approaches revealed that SOX10 repressed IRF1 transcription via direct induction of a negative regulator, IRF4.

[Purinergic Signalling] The authors explore and propose hypotheses with respect to the possibility that rosmarinic acid can be a promising and alternative compound to be used as an adjuvant in melanoma treatment, acting on purinergic signaling.

[Current Oncology Reports] Scientists review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with BRAF-mutated metastatic melanoma.

[The University of Queensland] University of Queensland researchers will lead the creation of a national blueprint for screening melanoma. Professor Monika Janda will head the research team after being awarded a $5 million Synergy Grant from the National Health and Medical Research Council.

[International Immunopharmacology] Scientists discuss the latest clinical data from clinical trials for immune-checkpoint inhibitors for the treatment of hepatocellular carcinoma.